A December 2020 review of RECOVERY’s lopinavir/ritonavir results in hospitalised patients with COVID-19. It discusses the lack of demonstrated benefit, the limits of extrapolating to earlier disease and how adaptive platform trials made rapid evaluation of proposed treatments possible.